960535-39-1 MDL NO.:
1) All the descriptions are subject to CAS number.
2) Please feel free to contact us if you need further assistance.
You can send e-mail to firstname.lastname@example.org,or,send your inquiry by click on the"Inquiry" button.
3) We will respond to you within 24 hours.
Niraparib, also known as MK4827, is an orally active, potent and selective poly(ADP-Ribose) polymerase (PARP) inhibitor that radiosensitizes human lung and breast cancer cells. Niraparib inhibits PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM respectively. Niraparib is currently in Phase 3 clinical trials for ovarian cancer and BRCA+ breast cancer.